GeoVax Labs (GOVX) Net Equity Issued and Repurchased (2012 - 2025)
GeoVax Labs (GOVX) posted quarterly Net Equity Issued and Repurchased of -$220.0 billion for Q4 2025, down 200.0% quarter-over-quarter from $220.0 billion in Q3 2025.
GeoVax Labs (GOVX) Net Equity Issued and Repurchased (2012 - 2025) Analysis & Trends
GeoVax Labs (GOVX) has reported Net Equity Issued and Repurchased for 11 consecutive years, with -$220.0 billion the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Equity Issued and Repurchased changed N/A year-over-year to -$220.0 billion; the TTM figure through Dec 2025 stood at $4.2 million (changed N/A YoY), while the FY2025 annual figure was $4.1 million, down 16.33% from the prior year.
- Net Equity Issued and Repurchased declined to -$220.0 billion in Q4 2025 per GOVX's latest filing, from $220.0 billion in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $220.0 billion in Q3 2025 and bottomed at -$220.0 billion in Q4 2025.
- Historically, Net Equity Issued and Repurchased has averaged $3.5 million across 4 years, with a median of $3.2 million in 2021.
- Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased slumped 100.0% — and 2025, when it jumped 106794461.24%.
- GeoVax Labs' Net Equity Issued and Repurchased stood at -$9.4 million in 2021, then surged by 394.69% to $27.7 million in 2022, then slumped by 99.26% to $206003.0 in 2024, then sank by 106794564.16% to -$220.0 billion in 2025.
- Business Quant data shows GOVX's Net Equity Issued and Repurchased at -$220.0 billion in Q4 2025, $220.0 billion in Q3 2025, and $3.8 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | GeoVax Labs | 2.88 Mn | -260,493.75 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -220.00 Bn |
| Dec 31, 2025 | -220.00 Bn |
| Sep 30, 2025 | 220.00 Bn |
| Sep 30, 2025 | 220.00 Bn |
| Mar 31, 2025 | 3.80 Mn |
| Mar 31, 2025 | 3.80 Mn |
| Sep 30, 2024 | 206,003.00 |
| Sep 30, 2024 | 206,003.00 |
| Jun 30, 2022 | 27.73 Mn |
| Jun 30, 2022 | 27.73 Mn |
| Mar 31, 2022 | 24.00 |
| Mar 31, 2022 | 24.00 |
| Sep 30, 2021 | -9.41 Mn |
| Sep 30, 2021 | -9.41 Mn |
| Jun 30, 2021 | 6.23 Mn |
| Jun 30, 2021 | 6.23 Mn |
| Mar 31, 2021 | 3.17 Mn |
| Mar 31, 2021 | 3.17 Mn |
| Mar 31, 2020 | 300,000.00 |
| Mar 31, 2020 | 300,000.00 |